🇺🇸 FDA
Pipeline program

Ixazomib

TB-MC010034

Approved small_molecule terminated

Quick answer

Ixazomib for Relapsed and/or Refractory Multiple Myeloma is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 4 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Relapsed and/or Refractory Multiple Myeloma
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials